ArticlePrecision radiation oncology2024
Lymphocytopenia following adjuvant radiotherapy for breast cancer.
Article in Precision radiation oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Performance of artificial intelligence-assisted ultrasound elastography in classifying benign and malignant breast tumors: a systematic review and meta-analysis.BMC medical imaging · 2025Pooled it
- Comparison of the analgesic efficacy of superficial and deep serratus anterior plane blocks in patients undergoing breast cancer surgery: a prospective randomized single blind study.BMC anesthesiology · 2026Trial
- Post‑translational modification‑governed immune states in cancer immunity: Biomarker implications for checkpoint competence, tumor visibility and immunotherapy resistance (Review).International journal of oncology · 2026Review
- A novel prognostic model integrating the skeletal muscle index and systemic immune-inflammation index improves outcome prediction in unresectable esophageal squamous cell carcinoma.The British journal of radiology · 2026Article
- Pan-cancer prioritization of CCDC69 reveals an immune-enriched and therapeutically sensitive breast cancer phenotype.Discover oncology · 2026Article
- Pan-cancer characterization of POSTN and its clinical and microenvironmental associations in ERScientific reports · 2026Article
- Mapping research trends in immune cell metabolic reprogramming in breast cancer: a parallel dual-database bibliometric study.Discover oncology · 2026Article
- TMEM132A is associated with metabolic reprogramming, macrophage-oriented immune remodeling, and breast cancer progression.Clinical and experimental medicine · 2026Article
- Normal tissue complication probability modeling of severe radiation-induced lymphopenia using blood dose for lung cancer patients treated with IMRT and IMPT.Frontiers in immunology · 2026Article
- The prognostic role of inflammation-based hematologic markers in stage I-III colorectal cancer: a retrospective analysis.BMC cancer · 2025Article
- Ultrasound-based radiomics model for predicting axillary lymph node metastasis of breast cancer.BMC medical imaging · 2025Article
- Comparative analysis of preoperative contrast-enhanced cone beam breast CT (CE-CBBCT) and MRI for differentiating pathological complete response from minimal residual disease in breast cancer.BMC medical imaging · 2025Article
- Novel immune-nutritional prognostic ratio predicts long-term survival in stage I-III colorectal cancer.Frontiers in oncology · 2025Article
- Radiotherapy improves survival in HER2-positive breast cancer with lung metastases: a retrospective study with artificial intelligence-based prognostic modeling.Frontiers in oncology · 2025Article
- Lymphopenia after palliative radiotherapy for vertebral metastases.Journal of radiation research · 2024Article
- Lymphocytopenia following adjuvant radiotherapy for breast cancer.Precision radiation oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We retrospectively analyzed breast cancer patients who received adjuvant radiotherapy to determine the incidence of lymphocytopenia and its risk factors. Methods: We reviewed 812 patients with breast cancer who received postoperative radiotherapy. Patients were divided into two groups based on the use of chemotherapy, and a generalized linear regression model was used to explore predictive factors for grade 2 or higher lymphocytopenia. We also examined the effect of lymphocytopenia on overall survival. Results: Grade 2 or higher lymphocytopenia was observed in 19.4% of patients who did not receive chemotherapy and 45.1% of patients who received chemotherapy. In multivariate analysis, bilateral disease, regional lymph node irradiation, and baseline lymphocytopenia were associated with lymphocytopenia in patients who did not receive cytotoxic chemotherapy. Regional lymph node irradiation, baseline lymphocytopenia, use of antimetabolites, and use of molecular-targeted agents were associated with lymphocytopenia in patients treated with chemotherapy. In the survival analysis, lymphocytopenia was associated with worse overall survival only in patients treated with cytotoxic chemotherapy ( Conclusion: The analysis revealed the incidence and risk factors of lymphocytopenia after postoperative radiotherapy in patients with breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.